Bristol-myers Squibb Compnay

Amit Kumar Chattopadhyay

James A Johnson

Joanne M Smallheer

Charles G Clark

Zulan Pi

Nicholas Ronald Wurtz

Pravin Sudhakar Shirude

Ellen K Kick

Meriah Neissel Valente

Balaji Seshadri

Vishweshwaraiah Baligar

Chandrasekhar Reddy Rachamreddy

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Phenylpyrrolidinone formyl peptide 2 receptor agonists

The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases. 

Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. 

Piperidinone formyl peptide 2 receptor agonists

Growing community of inventors

Bengaluru, India

Amit Kumar Chattopadhyay